JP6167248B2 - 新規なカンナビジオールキノン誘導体 - Google Patents
新規なカンナビジオールキノン誘導体 Download PDFInfo
- Publication number
- JP6167248B2 JP6167248B2 JP2016560647A JP2016560647A JP6167248B2 JP 6167248 B2 JP6167248 B2 JP 6167248B2 JP 2016560647 A JP2016560647 A JP 2016560647A JP 2016560647 A JP2016560647 A JP 2016560647A JP 6167248 B2 JP6167248 B2 JP 6167248B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pparg
- cells
- compounds
- vce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 cannabidiol quinone derivatives Chemical class 0.000 title claims description 26
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title description 21
- 229950011318 cannabidiol Drugs 0.000 title description 21
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title description 21
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 199
- 239000000203 mixture Substances 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 14
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 10
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 206010039710 Scleroderma Diseases 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 230000029663 wound healing Effects 0.000 claims description 7
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 206010072170 Skin wound Diseases 0.000 claims description 6
- 150000003973 alkyl amines Chemical class 0.000 claims description 6
- 230000036560 skin regeneration Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 150000004982 aromatic amines Chemical class 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 108010016731 PPAR gamma Proteins 0.000 description 139
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 134
- 210000004027 cell Anatomy 0.000 description 92
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 58
- CGGGAXJIRQSRPH-JTHBVZDNSA-N CCCCCC1=C(NCc2ccccc2)C(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(=O)C1=O Chemical compound CCCCCC1=C(NCc2ccccc2)C(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(=O)C1=O CGGGAXJIRQSRPH-JTHBVZDNSA-N 0.000 description 52
- 230000000694 effects Effects 0.000 description 49
- 239000000556 agonist Substances 0.000 description 38
- 230000004913 activation Effects 0.000 description 36
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 35
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 34
- 239000000243 solution Substances 0.000 description 31
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 30
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 30
- 239000003642 reactive oxygen metabolite Substances 0.000 description 29
- 229960004586 rosiglitazone Drugs 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- 230000027455 binding Effects 0.000 description 20
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical class O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229930003827 cannabinoid Natural products 0.000 description 17
- 239000003557 cannabinoid Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical compound C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 108010035532 Collagen Proteins 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 14
- 239000012190 activator Substances 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 108060001084 Luciferase Proteins 0.000 description 13
- 239000005089 Luciferase Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 230000003833 cell viability Effects 0.000 description 13
- 239000013068 control sample Substances 0.000 description 13
- 210000001700 mitochondrial membrane Anatomy 0.000 description 13
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 12
- 238000001704 evaporation Methods 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000004005 microsphere Substances 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 150000004053 quinones Chemical class 0.000 description 10
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 229940065144 cannabinoids Drugs 0.000 description 9
- 230000037319 collagen production Effects 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 229930195712 glutamate Natural products 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 102000000536 PPAR gamma Human genes 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 102000006255 nuclear receptors Human genes 0.000 description 7
- 108020004017 nuclear receptors Proteins 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 125000004151 quinonyl group Chemical group 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 6
- 102000023984 PPAR alpha Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CQMJEZQEVXQEJB-UHFFFAOYSA-N 1-hydroxy-1,3-dioxobenziodoxole Chemical compound C1=CC=C2I(O)(=O)OC(=O)C2=C1 CQMJEZQEVXQEJB-UHFFFAOYSA-N 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 5
- 101150116862 KEAP1 gene Proteins 0.000 description 5
- 231100000002 MTT assay Toxicity 0.000 description 5
- 238000000134 MTT assay Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 5
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 5
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000003531 protein hydrolysate Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 4
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 4
- 102100023118 Transcription factor JunD Human genes 0.000 description 4
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 4
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 4
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 4
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 3
- XDIAMRVROCPPBK-UHFFFAOYSA-N 2,2-dimethylpropan-1-amine Chemical compound CC(C)(C)CN XDIAMRVROCPPBK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NMHGHHJEIAOCKU-DOTOQJQBSA-N OC=1C(C(=C(C(C=1[C@@H]1C=C(CC[C@H]1C(=C)C)C)=O)C(=O)OC)CCCCC)=O Chemical compound OC=1C(C(=C(C(C=1[C@@H]1C=C(CC[C@H]1C(=C)C)C)=O)C(=O)OC)CCCCC)=O NMHGHHJEIAOCKU-DOTOQJQBSA-N 0.000 description 3
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000011759 adipose tissue development Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 3
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000003959 neuroinflammation Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 3
- 239000008024 pharmaceutical diluent Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000004059 quinone derivatives Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 2
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241001609030 Brosme brosme Species 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 2
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 108010028924 PPAR alpha Proteins 0.000 description 2
- 108010015181 PPAR delta Proteins 0.000 description 2
- 108010044210 PPAR-beta Proteins 0.000 description 2
- 101150023417 PPARG gene Proteins 0.000 description 2
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000003667 anti-reflective effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003492 excitotoxic effect Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 102000048068 human COL1A2 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002705 metabolomic analysis Methods 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000001703 neuroimmune Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940100684 pentylamine Drugs 0.000 description 2
- 239000003614 peroxisome proliferator Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DTGKSKDOIYIVQL-SFVIPPHHSA-N (4s)-4,7,7-trimethylbicyclo[2.2.1]heptan-3-ol Chemical compound C1C[C@]2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-SFVIPPHHSA-N 0.000 description 1
- YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VXKXBJVMZNMHLS-DLTAVPQMSA-N 2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentyl-5-[(1R,2R,4R)-1,5,5-trimethyl-2-bicyclo[2.2.1]heptanyl]benzoic acid Chemical compound CCCCCc1c([C@@H]2C[C@@H]3C[C@]2(C)CC3(C)C)c(O)c([C@@H]2C=C(C)CC[C@H]2C(C)=C)c(O)c1C(O)=O VXKXBJVMZNMHLS-DLTAVPQMSA-N 0.000 description 1
- CXEVNOLTPGYWAE-VVAFYCBGSA-N 2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentyl-5-[(1S,2S,4R)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]benzoic acid Chemical compound CCCCCc1c([C@H]2C[C@H]3CC[C@]2(C)C3(C)C)c(O)c([C@@H]2C=C(C)CC[C@H]2C(C)=C)c(O)c1C(O)=O CXEVNOLTPGYWAE-VVAFYCBGSA-N 0.000 description 1
- JCYPDKSGYHGCCY-UHFFFAOYSA-N 2-pentylbenzoic acid Chemical compound CCCCCC1=CC=CC=C1C(O)=O JCYPDKSGYHGCCY-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- PNAKUQDGWQNBAP-UHFFFAOYSA-N 3,6-dioxo-2-pentylcyclohexa-1,4-diene-1-carboxylic acid Chemical compound CCCCCC1=C(C(=O)C=CC1=O)C(=O)O PNAKUQDGWQNBAP-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- IEJVYSKNMZZEFR-GOEBONIOSA-N CCCCCC(C(C(O)=C1[C@@H]2C=C(C)CC[C@H]2C(C)=C)=O)=C(C(O)=O)C1=O Chemical compound CCCCCC(C(C(O)=C1[C@@H]2C=C(C)CC[C@H]2C(C)=C)=O)=C(C(O)=O)C1=O IEJVYSKNMZZEFR-GOEBONIOSA-N 0.000 description 1
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010033714 Maf Transcription Factors Proteins 0.000 description 1
- 102000007307 Maf Transcription Factors Human genes 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- NXLRFEBDSYFKNW-LADGPHEKSA-N OC=1C(C(=C(C(C=1[C@@H]1C=C(CC[C@H]1C(=C)C)C)=O)C(=O)OCCC1=CC=CC=C1)CCCCC)=O Chemical compound OC=1C(C(=C(C(C=1[C@@H]1C=C(CC[C@H]1C(=C)C)C)=O)C(=O)OCCC1=CC=CC=C1)CCCCC)=O NXLRFEBDSYFKNW-LADGPHEKSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150110386 SLC2A4 gene Proteins 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 231100000131 acute cytotoxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- SMBBZHGTZJNSRQ-UHFFFAOYSA-N n'-(6,6-dichlorohexyl)methanediimine Chemical compound ClC(Cl)CCCCCN=C=N SMBBZHGTZJNSRQ-UHFFFAOYSA-N 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
- C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
- C07C225/28—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of non-condensed quinone rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/95—Esters of quinone carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
式中、Rは、アルキル、アリール、アルケニル、アルキニル、アシル、またはアルコキシカルボニルの基によって表される直鎖または分枝鎖の基の炭素原子であるか、あるいは、Rは、アルキルアミン、アリールアミン、アルケニルアミン、またはアルキニルアミンの基によって表される直鎖または分枝鎖の基の窒素原子である。本発明のCBD−Q誘導体を与えるためにキノン環のどの位置で置換基の交換が行われるかを示すために、キノン環には任意に番号が付された。IUPAT命名法が許可し得ることがある限り、キノン環の番号付けは維持される(式II乃至Xの誘導体を参照。前記キノン環の位置3はすべての置換基交換が生じた位置であり、前述の誘導体の命名法はその事実に一致かつ反映したものである)。しかしながら、キノン環の位置3に結合した置換基群が、IUPAT命名法により義務化された前述のキノン環の位置の番号付けを変更した場合、外見上でのみキノン環の位置3での交換は明らかに失われるものの(式XI乃至XVにより表される誘導体の構造式によって示されるように実際にそうではないが)、その結果の用語が使用された。
略語:
AP−1:アクチベータプロテイン−1
ARE:抗酸化剤に反応する要素
CBD:カンナビジオール
CBDA:カンナビジオール酸
CBD−Q:カンナビジオールキノン
CBG−Q:カンナビゲロールキノン(VCE−003とも称される)
DCC:ジクロロへキシルカルボジイミド
Keap1:Kelch ECH関連タンパク質1
NFAT:活性化T細胞の核因子
NFE2L2又は(Nrf2):核因子(赤血球由来2)−様2
NF−kB:核因子−カッパB
NP:神経細胞前駆体
NR1C:核のサブファミリー1C
NRs:核内受容体
PPARs:ペルオキシソーム増殖因子活性化受容体
PPARg:PPARγ、グリタゾン受容体、又はNR1C3とも称される、ペルオキシソーム増殖因子活性化受容体ガンマ
PPARg−m:PPARgモジュレータ
PPARg−fa:PPARg完全アゴニスト
PPARα:NR1C1とも称されるペルオキシソーム増殖因子活性化受容体アルファ
PPARβ/δ:NR1C2とも称されるペルオキシソーム増殖因子活性化受容体ベータ/アルファ
PPRE:ペルオキシソーム増殖因子反応要素
ROS:活性酸素種
STAT3:シグナルトランスデューサ及び転写3の信号の活性化因子
TGFb:トランスフォーミング成長因子ベータ
VCE−004:カンナビジオールキノン化合物;HU−331及び化合物Iとも称される
HU−331:カンナビジオールキノン化合物;VCE−004及び化合物Iとも称される
図中の略語:
I:VCE−004(CBD−Q)を指す。
II:式(II)の化合物を指す。
III:式(III)の化合物を指す。
IV:式(IV)の化合物を指す。
V:式(V)の化合物を指す。
VI:式(VI)の化合物を指す。
VII:式(VII)の化合物を指す。
VIII:式(VIII)の化合物を指す。
IX:式(IX)の化合物を指す。
X:式(X)の化合物を指す。
XI:式(XI)の化合物を指す。
XII:式(XII)の化合物を指す。
XIII:式(XIII)の化合物を指す。
XIV:式(XIV)の化合物を指す。
XV:式(XV)の化合物を指す。
A)CBDから出発するCBDキノン誘導体の合成。化合物II乃至Xの合成。
CBDからのVCE−004(HU−331又は化合物Iとも称される)の合成を、大気の存在下、室温で、トルエン中のtBuOKを使用することにより行なった(模式図1)。アルキルアミンにより3つの位置で置換された誘導体の合成を、大気開放反応システムにおいて室温で、VCE−004を過剰なアミンと反応させることにより容易に達成した。
tBuOK(298mg、2.656mmol)をトルエン(60mL)中のCBD(302mg、0.960mmol)の溶液に加え、紫色の溶液を得た。反応混合物を大気開放丸底フラスコの中、室温で撹拌し、転換率をTLC分析(溶離剤:10%のEtOAc/ヘキサン)によりモニタリングした。4時間後、反応混合物をHCl(5%の水溶液、100mL)で洗浄し、水層をEtOAc(30mL)で抽出した(模式図2)。組み合わせた有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物をSiO2(0@20% EtOAc/ヘキサン)の上でフラッシュクロマトグラフィー分離して、234mgのVCE−004(化合物I)を得た[茶色の固形物、収率:74%]。
(1’R,6’R)−3−(エチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
エチルアミン(1.0mL、H2O、12.58mmolをEtOH(10mL)中のVCE−004(100mg、0.30mmol)の溶液に加えた。反応混合物を2時間、室温で撹拌し、そして水(50mL)に注ぎ、HCl(10%の水溶液)でpH=2に酸性化し、CH2Cl2(30mL)で抽出することで、加工処理した(worked)(模式図3)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、33mgの(1’R,6’R)−3−(エチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の油、収率:29%]。
1H NMR(CDCl3、300MHz)d ppm:6.35(bs、1H)、5.13(s、1H)、4.57(s、2H)、3.61(m、1H)、3.52(quin、J=13.2、7.1Hz、2H)、2.73(m、1H)、2.48(t、J=7.1Hz、2H)、2.26−1.80(m、2H)、1.68(s、3H)、1.63(s、3H)、1.46−1.24(m、9H)、0.89(t、J=6.6Hz、3)。
(1’R,6’R)−3−(ペンチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
アミルアミン(0.75mL、6.472mmol)をEtOH(10mL)中のVCE−004(60mg、0.155mmol)の溶液に加えた。反応混合物を18時間、室温で撹拌した。それをH2O(50mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(30mL)で抽出した(模式図4)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、47mgの(1’R,6’R)−3−(ペンチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の固形物、収率:73%]。
1H NMR(CDCl3、300MHz)d ppm:6.43(bs、1H)、5.14(s、1H)、4.55(s、2H)、3.62(m、1H)、3.46(c、J=6.6Hz、2H)、2.72(m、1H)、2.48(t、J=7.7Hz、2H)、2.31−1.72(m、4H)、1.68(s、3H)、1.64(s、3H)、1.48−1.24(m、12H)、0.90(m、6H)。
(1’R,6’R)−3−(イソブチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
イソブチルアミン(1.2mL、12.075mmol)をEtOH(12mL)中のVCE−004(100mg、0.304mmol)の溶液に加えた。反応混合物を22時間、室温で撹拌した。それをH2O(50mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(30mL)で抽出した(模式図5)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、119mgの(1’R,6’R)−3−(イソブチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の固形物、収率:97%]。
1H NMR(CDCl3、300MHz)d ppm:6.53(bs、1H)、5.15(s、1H)、4.56(s、2H)、3.62(m、1H)、3.27(t、J=6.6Hz、2H)、2.73(dt、J=12.0Hz、2.8Hz、1H)、2.47(t、J=7.1Hz、2H)、2.27−1.72(m、4H)、1.68(s、3H)、1.64(s、3H)、1.47−1.29(m、7H)、1.00(s、3H)、0.97(s、3H)、0.89(t、J=6.6Hz、3)。
(1’R,6’R)−3−(ブチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
n−ブチルアミン(1.2mL、12.143mmol)をEtOH(12mL)中のVCE−004(109mg、0.332mmol)の溶液に加えた。反応混合物を18時間、室温で撹拌した。それをH2O(50mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(30mL)で抽出した(模式図6)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、115mgの(1’R,6’R)−3−(ブチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の固形物、収率:93%]。
1H NMR(CDCl3、300MHz)d ppm:6.44(bs、1H)、5.14(s、1H)、4.56(s、2H)、3.61(m、1H)、3.46(q、J=6.6Hz、2H)、2.73(m、1H)、2.48(t、J=7.1Hz、2H)、2.19(m、1H)、1.98(m、1H)、1.78−1.57(m、8H)、1.49−1.25(m、10H)、0.96(t、J=7.1Hz、3H)、0.89(m、3H)。
(1’R,6’R)−3−(メチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
メチルアミン(4.0mL、EtOH中の8Mの溶液、32.0mmol)をEtOH(20mL)中のVCE−004(266mg、0.810mmol)の溶液に加えた。反応混合物を7時間、室温で撹拌した。それをH2O(100mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(70mL)で抽出した(模式図7)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、114mgの(1’R,6’R)−3−(メチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の固形物、収率:39%]。
1H NMR(CDCl3、300MHz)d ppm:8.38(bs、1H)6.54(m、1H)、5.12(s、1H)、4.56(s、2H)、3.63(m、1H)、3.19(d、J=6.0Hz、3H)、2.71(dt、J=11.5Hz、2.7Hz、1H)、2.54(t、J=7.1Hz、2H)、2.28−1.71(m、3H)、1.67(s、3H)、1.63(s、3H)、1.51−1.25(m、6H)、0.89(t、J=7.1Hz、3H)。
(1’R,6’R)−3−(イソプロピルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
イソプロピルアミン(1.0mL、11.639mmol)をEtOH(10mL)中のVCE−004(104mg、0.317mmol)の溶液に加えた。反応混合物を22時間、室温で撹拌した。それをH2O(50mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(30mL)で抽出した(模式図8)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、92mgの(1’R,6’R)−3−(イソプロピルアミン(Isopropylamino))−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の油、収率:75%]。
1H NMR(CDCl3、300MHz)d ppm:6.40(m、1H)、5.14(s、1H)、4.56(s、2H)、3.95(m、1H)、3.61(m、1H)、2.73(m、1H)、2.45(t、J=6.6Hz、2H)、2.21(m、1H)、1.92(m、1H)、1.77(m、2H)、1.67(s、3H)、1.63(s、3H)、1.45−1.28(m、6H)、1.26(s、3H)、1.24(s、3H)、0.89(t、J=7.1Hz、3H)。
(1’R,6’R)−3−(ベンジルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
ベンジルアミン(1.3mL、11.913mmol)をEtOH(13mL)中のVCE−004(117mg、0.303mmol)の溶液に加えた。反応混合物を18時間、室温で撹拌した。それをH2O(50mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(30mL)で抽出した(模式図9)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、87mgの(1’R,6’R)−3−(ベンジルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の固形物、収率:66%]。
1H NMR(CDCl3、300MHz)d ppm:8.30(bs、1H)、7.44−7.26(m、5H)、6.64(m、1H)、5.15(s、1H)、4.65(d、J=6.0Hz、2H)、4.59(m、2H)、3.64(m、1H)、2.73(m、1H)、2.47(t、J=7.7Hz、2H)、2.30−1.76(m、4H)、1.68(s、3H)、1.64(s、3)、1.54−1.23(m、6H)、0.88(m、3H)。
(1’R,6’R)−3−(ネオペンチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
ネオペンチルアミン(0.7mL、6.031mmol)をEtOH(7mL)中のVCE−004(47mg、0.143mmol)の溶液に加えた。反応混合物を20時間、室温で撹拌した。それをH2O(50mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(30mL)で抽出した(模式図10)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、57mgの(1’R,6’R)−3−(ネオペンチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の油、収率:97%]。
1H NMR(CDCl3、300MHz)d ppm:6.59(m、1H)、5.15(s、1H)、4.56(s、2H)、3.63(m、1H)、3.26(d、J=5.5Hz、2H)、2.74(dt、J=12.0Hz、3.3Hz、1H)、2.49(t、J=7.1Hz、2H)、2.26−1.83(m、3H)、1.68(s、3H)、1.63(s、3H)、1.50−1.23(m、7H)、1.00(s、9H)、0.90(t、J=6.6Hz、3H)。
(1’R,6’R)−3−(イソペンチルアミン−6−ヒドロキシ)−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオン
イソペンチルアミン(1.5mL、12.735mmol)をEtOH(15mL)中のVCE−004(101mg、0.307mmol)の溶液に加えた。反応混合物を22時間、室温で撹拌した。それをH2O(50mL)に注ぎ、HCl(10%の水溶液)によりpH=2にまで引き上げ、CH2Cl2(30mL)で抽出した(模式図11)。有機質層をNa2SO4(無水)で乾燥し、濾過し、濃縮した。粗製の残留物を、逆相クロマトグラフィー(30@100% CH3CN/H2O)により精製して、125mgの(1’R,6’R)−3−(イソペンチルアミン)−6−ヒドロキシ−3’−メチル−4−ペンチル−6’−(プロプ−1−エン−2−イル)−[1,1’−ビ(シクロヘキサン)]−2’,3,6−トリエン−2,5−ジオンを得た[紫色の油、収率:98%]。
1H NMR(CDCl3、300MHz)d ppm:6.38(bs、1H)、5.13(s、1H)、4.55(s、2H)、3.61(m、1H)、3.48(q、J=6.0Hz、2H)、2.72(m、1H)、2.48(t、J=7.1Hz、2H)、2.21(m、1H)、2.00−1.60(m、8H)、1.54(q、J=7.1Hz、2H)、1.46−1.23(m、8H)、0.95(s、3H)、0.93(s、3H)、0.88(t、J=6.6Hz、3H)。
メチル4−ヒドロキシ−5−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−3,6−ジオキソ−2−ペンチルシクロヘキサ−1,4−ジエンカルボキシラート(CBDA−メチルエステル)
1H NMR(CDCl3、300MHz)d ppm:11.97(s、1H)、6.40(bs、1H)、6.21(s、1H)、5.54(bs、1H)、4.51(bs、1H)、4.38(bs、1H)、3.90(s、3H)、2.77(m、2H)、1.81(bs、3H)、1.70(bs、3H)、0.89(t、J=6.6Hz、3H)。
メチル4−ヒドロキシ−5−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−3,6−ジオキソ−2−ペンチルシクロヘキサ−1,4−ジエンカルボキシラート
1H NMR(CDCl3、300MHz)d ppm 7.00(bs、1H)、5.13(bs、1H)、4.57(s、1H)、4.53(s、1H)、3.89(s、3H)、3.73(bd、J=7.0Hz、1H)、2.74(td、J=9、1、9.1、1.5Hz、1H)、2.36(t、J=7.5Hz、2H)、1.72(bs、3H)、1.64(bs、3H)、0.88(t、J=6.6Hz、3H)。
フェネチル2,4−ジヒドロキシ−3−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−6−ペンチルベンゾアート(CBDA−フェネチルエステル)
1H NMR(CDCl3、300MHz)d ppm 12.0(s、1H)、7.35−7.24(m、1H)、6.51(bs、1H)、6.21(s、1H)、5.55(bs、1H)、4.55(t、J=7.5Hz、1H)、4.53(bs、1H)、4.38(bs、1H)、4.10(bs、1H)、3.10(t、J=7.5Hz、2H)、2.70(m、2H)、1.79(bs、3H)、1.71(bs、3H)、0.88(t、J=6.6Hz、3H)。
フェネチル4−ヒドロキシ−5−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−3,6−ジオキソ−2−ペンチルシクロヘキサ−1,4−ジエンカルボキシラート
1H NMR(CDCl3、300MHz)d ppm 7.00(bs、1H)、5.14(bs、1H)、4.54(s、1H)、4.52(s、1H)、4.51(t、J=7.5Hz)、3.74(bd、J=7.0Hz、1H)、3.02(t、J=7.5Hz、2H)、2.75(br t、J=9、1、1.5Hz、1H)、2.26(t、J=7.5Hz、2H)、1.74(bs、3H)、1.67(bs、3H)、0.86(t、J=6.6Hz、3H)。
(E)−3,7−ジメチルオクタ−2,6−ジエニル2,4−ジヒドロキシ−3−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−6−ペンチルベンゾアート(CBDA−ゲラニルエステル)
1H NMR(CDCl3、300MHz)d ppm 12.1(s、1H)、6.48(bs、1H)、6.20(s、1H)、5.54(bs、1H)、5.45(brt、J=6.7Hz、1H)、5.08(br s、1H)、4.81(d、J=6,7Hz、2H)、4.51(bs、1H)、4.38(bs、1H)、4.08(bs、1H)、2.74(m、2H)、1.78(bs、3H)、1.75(bs、3H)、1.71(bs、3H)、1.67(bs、3H)、0.88(t、J=6.6Hz、3H)。
(E)−3,7−ジメチルオクタ−2,6−ジエニル−4−ヒドロキシ−5−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−3,6−ジオキソ−2−ペンチルシクロヘキサ−1,4−ジエンカルボキシラート
1H NMR(CDCl3、300MHz)d ppm 6.99(bs、1H)、5.38(bt、J=6.8Hz、1H)、5.12(bs、1H)、5.07(bs、1H)、4.81(bs、1H)、4.80(bs、1H)、4.56(bs、1H)、3.97(d、J=6.8Hz、2H)、2.73(m、1H)、2.37(m、2H)、1.73(bs、3H)、1.70(bs、3H)、1.67(bs、3H)、1.62(bs、3H)、0.86(t、J=6.9、3H)。
(1S,2S,4R)−1,7,7−トリメチルビシクロ[2.2.1]ヘプタン−2−イル−2,4−ジヒドロキシ−3−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−6−ペンチルベンゾアート(CBDAボルニルエステル)
1H NMR(CDCl3、300MHz)d ppm 12.2(s、1H)、6.48(bs、1H)、6.23(s、1H)、5.54(bs、1H)、5.54(bs、1H)、5.19(br s、1H)、4.52(bs、1H)、4.40(bs、1H)、4.12(bs、1H)、2.91(m、2H)、1.80(bs、3H)、1.71(bs、3H)、0.96(s、3H)、0.89(s、6H)、0.88(t、J=6.6Hz、3H)。
((1S,2S,4R)−)−1,7,7−トリメチルビシクロ[2.2.1]ヘプタン−2−イル−4−ジヒドロキシ−5−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−3,6−ジオキソ−2−ペンチルシクロヘキサ−1,4−ジエンカルボキシラート
1H NMR(CDCl3、300MHz)d ppm 6.98(bs、1H)、5.16(bs、1H)、5.10(bd、J=10Hz、1H)、4.58(bs、1H)、4.56(bs、1H)、3.75(bd、J=6.8Hz、1H)、2.73(m、1H)、2.37(m、2H)、1.61(bs、3H)、0.92(s、3H)、0.90(s、3H)、0.88(bs、3H)、0.86(t、J=6.9、3H)。
(1R,2R,4R)−1,5,5−トリメチルビシクロ[2.2.1]ヘプタン−2−イル−2,4−ジヒドロキシ−3−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−6−ペンチルベンゾアート(CBDAフェンキルエステル)
1H NMR(CDCl3、300MHz)d ppm 12.34(s、1H)、6.50(bs、1H)、6.24(s、1H)、5.57(bs、1H)、4.64(bs、1H)、4.52(bs、1H)、4.39(bs、1H)、4.10(bs、1H)、2.97(m、2H)、1.71(bs、3H)、1.20(s、3H)、1.14(s、3H)、0.96(s、3H)、0.89(s、6H)、0.89(t、J=6.6Hz、3H)、0.79(s、3H)。
(1R,2R,4R)−1,5,5−トリメチルビシクロ[2.2.1]ヘプタノ−2−イル4−ヒドロキシ−5−((1R,6R)−3−メチル−6−(プロプ−1−エン−2−イル)シクロヘキサ−2−エニル)−3,6−ジオキソ−2−ペンチルシクロヘキサ−1,4−ジエンカルボキシラート
1H NMR (CDCl3, 300 MHz) d ppm 6.98 (bs,1H), 5.16 (bs,1H), 5.10 (bd,J=10Hz, 1H), 4.60 (bs,1H), 4.57 (bs,1H), 4.55 (bs,1H), 3.73 (bd,J=10Hz, 1H), 2.73 (m,1H), 2.38 (m,2H), 1.67 (bs,3H), 1.15 (s,3H), 1.10 (s,3H), 0.86 (s,3H), 0.86 (t,J= 6.9, 3H).
実施例2.PPARgのアゴニスト活性
新規な化合物の生物学的活性を調査するために、我々は、HEK−293細胞、およびNIH−3T3繊維芽細胞のPPARgトランスアクチベーション分析を行った。
HEK293T細胞とヒト原発性の繊維芽細胞を、10%のウシ胎児血清(FBS)で補充したDMEM中に5%のCO2と1%(v/v)ペニシリン/ストレプトマイシンを含む湿気のある大気中で37°Cで維持した。ロシグリタゾンをCayman Chemical Company(米国ミシガン州アン・アーバー)から購入した。他のすべての試薬はSigma Co(米国ミズーリ州セントルイス)から入手した。HEK293T細胞(2x103/ウェル)(図1A、1B、および1C)、またはNIH3T3細胞(5x103/ウェル)(図2)を、24時間、Clear Bottom 96ウェルのMicrotest(商標)Optilux(商標)Plateを伴うBD Falcon(商標)Whiteに播種した。その後、メーカーの説明書に従ってRoti(著作権)−Fect(ドイツ カールスルーエ カールロート(Carl Roth))を使用して、細胞を、発現ベクターGAL4PPARγとルシフェラーゼリポーターベクターGAL4−lucで一時的に同時トランスフェクトした。24時間のトランスフェクション後、細胞を6時間、化合物の漸増用量で前処理した。その後、細胞を、25mMのトリリン酸塩pH7.8、8mMのMgCl2、1mMのDTT、1%のトリトンX−100、および7%のグリセリン中に溶解させた。ルシフェラーゼ活性は、TriStar LB 941マルチモードマイクロプレートリーダ(Berthold)を用いて、ルシフェラーゼアッセイキット(Promega,米国ウィスコンシン州マジソン)の説明書に従って、細胞溶解産物中で測定された。タンパク質濃度はBradfordアッセイ(Bio−Rad,米国カリフォルニア州リッチモンド)によって測定された。溶解バッファーで得られたバックグラウンドは、各実験値と、未処置の細胞上の誘導倍率として表現された特定のトランスアクチベーションの中で引かれた。実験はすべて少なくとも3回繰り返された。使用されるプラスミドは、Gal4−hPPARgamma(プラスミド名:pCMV−BD−hPPARg,ダルフージー大学薬理学部Sinal Laboratory)と、ルシフェラーゼ遺伝子に縮合した5つのGal4 DNA結合部位を含むGal4 lucレポータープラスミドであった。上記の分析は図1(A、B、およびC)と図2によって例証され、これは、ルシフェラーゼレポーター遺伝子(PPARgGAL4/GAL4−LUC)と組み合わせてPPARgを一時的に過剰発現するとともに6時間にわたって化合物で処置された細胞で行われるトランスアクチベーションアッセイによるPPARg活性に対するVCE−004(化合物I)とアナログの効果を示す。データは3つの複製の偏差標準誤差棒を備えた手段として与えられる。未処置の細胞と比較して、ルシフェラーゼ活性の有意な増大はキノン誘導体で見られた。この結果は化合物II乃至XIVが、5〜50μMの濃度でPPARgを活性化するために化合物VCE−004(化合物I)よりも著しく有力であることを確認する。化合物II乃至Xは濃度依存的な手法でPPARgトランスアクチベーションを増大させ、化合物II、III、IV、V、VII、およびVIIIが最も活性な化合物である。加えて、高濃度のこうした化合物(10、25、および50μM)は、VCE−004(化合物I)と比較して、PPARgを活性化するのに特に有力である。RZG(十分なPPARgアゴニスト)は、1μMの濃度でPPARgの活性を100倍以上増加させた。対照的に、本発明に記載される1μMの濃度の化合物により引き起こされるPPARg活性の最大の誘発はけっして5倍以上にはならず、このことは、こうした新規な化合物がPPARgモジュレータであり、PPARg完全アゴニストではないことを示唆している。
(A)HEK293T細胞は、10%のウシ胎児血清(FBS)で補充したDMEM中の5%のCO2と1%(v/v)のペニシリン/ストレプトマイシンを含む湿った大気中で37°Cで維持された。ロシグリタゾンをCayman Chemical Company(米国ミシガン州アン・アーバー)から購入した。HEK293T細胞(2x103/ウェル)(図3A)を、24時間、Clear Bottom 96ウェルのMicrotest(商標)Optilux(商標)Plateを伴うBD Falcon(商標)Whiteで播種した。その後、メーカーの説明書に従ってRoti(著作権)−Fect(ドイツ カールスルーエ カールロート(Carl Roth))を使用して、細胞を、発現ベクターGAL4PPARγとルシフェラーゼリポーターベクターGAL4−lucで一時的に同時トランスフェクトした。24時間のトランスフェクション後、細胞は30分間、漸増用量の化合物で前処理され、その後、6時間RSZ(1μM)で刺激された。PPARgの転写活性は実施例2のように測定され、こうした化合物III、V、VIII、X、およびXIIIはRSZにより引き起こされたPPARgトランスアクチベーションを減少させることができ、したがって、化合物III、V、VIII、X、およびXIIIとRSZがPPARg上の同じ結合部位に結合することを示唆している。
求電子のキノンは細胞毒性を引き起こし、Nrf2経路(活性酸素種生成の細胞のセンサー)を活性化する。図4では、それは、化合物VCE−004(化合物I)と化合物II乃至XVによる3つの異なるタイプの細胞型N2a(A)、HT22(B)、およびMO3.13(C)において引き起こされた細胞死について分析される。
Nrf2経路上の化合物の活性を研究するために、我々はHaCaT−ARE−Luc細胞株を生成した。Nqo1 ARE−LucレポータープラスミドとpPGK−Puroプラスミドは、Lipofectamine(著作権)2000年トランスフェクション試薬(Life Technologies,米国カリフォルニア州カールスバッド)を使用して、HaCat細胞へ同時にトランスフェクトされた。安定した形質転換体が選択され、10%のFBS、1%のペニシリン・ストレプトマイシン、および10μl/mlのピューロマイシンを含むRPMI 1640で維持された。HaCaT−ARE−Luc細胞は、指示された濃度でVCE−004(化合物I)と化合物II乃至VIII(A)または化合物IX乃至XV(B)で6時間培養され、タンパク質溶解産物は実施例1に記載されるようなルシフェラーゼ活性のために調製され、分析された。20μMの酸化体tert−ブチルヒドロキノン(tBHQ)は陽性対照として使用された。倍活性化レベルは、基準(図5Aと5B)として対照サンプル(−)をとって計算された。データは少なくとも3つの独立した実験からの平均±S.D.として表される。その結果は、VCE−004(化合物I)に関連する反応的な求電子の活性が本発明に記載のすべての化合物(位置4の誘導体)でかけていることを承認する。
核受容体PPARgの活性化は神経保護において重要な役割を果たしており、PPARgアゴニストが神経細胞中のグルタミン酸塩により引き起こされた細胞毒性を防ぐことが知られている。
PPARgリガンドは抗繊維症の効果を及ぼすことが報告されており、PPARg活性化によるTGFbシグナル伝達の阻害は繊維芽細胞におけるコラーゲン産生の減少をもたらす。
コラーゲンの産生は、細胞ペレット剤中のコラーゲンと非コラーゲンのタンパク質の量を定量化するために設計されるSirius Red−Fast Green方法を使用して行われる。NIH3T3細胞は24ウェル中の5×104/ウェルの密度で播種され、細胞接着を可能にするために37°Cで夜通し培養された。次に、細胞は、24時間のあいだに、指示された濃度の化合物III、V、VIII、およびXとTGFb(50ng/ml)で1時間事前培養された。処置の後、細胞ペレット剤は、100μlの0.5M酢酸で4°Cで夜通し抽出された。その後、1mlの染料溶液(飽和したピクリン酸に溶解した0.1%のSirius Redと0.1%のFast Green)が細胞ペレット剤に加えられ、30分間室温で優しく混合された。次に、コラーゲンをペレット化するために5分間10,000gでサンプルを遠心分離機にかけた。ペレット剤を乱すことなく上澄みを注意深く取り除き、0.1Mの塩酸の1mlを各チューブに加えて非結合染料を取り除いた。サンプルを5分間10,000gで遠心分離機にかけ、0.5Mの水酸化ナトリウム1mlを各チューブと渦に勢いよく加えて、結合染料を放出した。どんな細胞残屑もペレット化するためにサンプルを再度、5分間2500gで遠心分離機にかけた。コラーゲン産生が判定され、その結果は未処置の細胞の誘導倍率として表現された。化合物III、V、VIII、およびXが繊維芽細胞においてTGFbにより引き起こされたコラーゲン産生を明白に抑制したことが示される(図8)。VCE−004(HU−331)に関連する細胞毒性では、TGFbにより引き起こされたコラーゲン産生に対するこの化合物の効果を調査することはできなかった。
ミトコンドリア膜電位は、ATPを生成するために呼吸鎖の生理学的機能を維持するために必要不可欠である。ミトコンドリア膜電位の重要な喪失により、細胞はその後の死に伴ってエネルギーを失う。したがって、ミトコンドリア膜電位とROSを決定する能力は、求電子分子と反応分子に応じて細胞の生理的な状態とミトコンドリアの機能に関する重要な手掛かりを提供することができる。
10mgのVCE−004(化合物I)と化合物XI(前述の誘導体II乃至XとXII乃至XVの化合物ファミリーの他のメンバーに適用可能な、本発明のCBD誘導体の例として)は、1mLのDMSO中に独立して溶解され、溶液は過剰な(4mol.同等物)システアミンで処置された。1時間室温で撹拌した後に、溶液を水(2mL)で希釈し、石油エーテル−エーテル9:1で抽出した。蒸発の後、残基はCDCl3に溶かされ、1H−NMRによって分析された。化合物XIは無傷のまま回復したが、VCE−004(I)は完全に反応し、残基中では検出不可能であり、このことはVCE−004がシステアミンに不可逆的に結合したことを示す。
・Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. 2013. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 19:557−66
・Barish GD, Narkar VA, Evans RM. 2006. PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest. 116:590−597
・Bernardo A, Minghetti L. 2008. Regulation of Glial Cell Functions by PPAR−gamma natural and Synthetic Agonists. PPAR Res. 864140.
・Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. 2000. Role of quinones in toxicology. Chem Res Toxicol. 3:135−60.
・Burstein S. 2005. PPAR−gamma: a nuclear receptor with affinity for cannabinoids. Life Sci. 77:1674−84.
・Ciudin A, Hernandez C, SimoR. 2012. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Curr Top Med Chem. 12: 585−604.
・Doshi LS, Brahma MK, Bahirat UA, Dixit AV, Nemmani KV. 2012. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin Investig Drugs. 19:489−512.
・Ferguson HE, Kulkarni A, Lehmann GM, Garcia−Bates TM, Thatcher TH, Huxlin KR. et al. 2009. Electrophilic peroxisome proliferator−activated receptor−gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol. 41:722−30.
・Fievet C, Fruchart JC, Staels B. 2006. PPAR alpha and PPAR gamma dual agonists for the treatment of type2 diabetes and the metabolicsyndrome. Curr. Opin. Pharmacol. 6: 606−614.
・Gelman, L., Feige, J.N., Desvergne, B. 2007. Molecular basis of selective PPARgamma modulation for the treatment of type 2 diabetes. Biochim. Biophys.Acta 1771: 1094−1107.
・Ghoochani A, Shabani K, Peymani M, Ghaedi K, Karamali F, Karbalaei K, Tanhaie S, Salamian A, Esmaeili A, Valian−Borujeni S, Hashemi M, Nasr−Esfahani MH, Baharvand H. 2012. The influence of peroxisome proliferator−activated receptor g(1) during differentiation of mouse embryonic stem cells to neural cells. Differentiation. 83: 60−67
・Granja AG, Carrillo−Salinas F, Pagani A, Gomez−Canas M, Negri R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Cantarero I, Calzado MA, Bellido ML, Fernandez−Ruiz J, Appendino G, Guaza C, Munoz E. 2012. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J Neuroimmune Pharmacol. 4:1002−1016
・Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JW. 2008. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 15:924−931.
・Kogan NM, Rabinowitz R, Levi P, Gibson D, Sandor P, Schlesinger M, and Mechoulam R. 2004. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 47: 3800−3806
・Lehmann JM, Moore LB, Smith−Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator−activated receptor gamma (PPAR gamma). J Biol Chem. 270:12953−12956.
・Li Y, Zhang J, Schopfer FJ, Martynowski D, Garcia−Barrio MT, Kovach A, Suino−Powell K, Baker PR, Freeman BA, Chen YE, Xu HE. 2008. Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol 15: 865−867
・Liberato MV, Nascimento AS, Ayers SD, Lin JZ, Cvoro A, Silveira RL, Martinez L, Souza PC, Saidemberg D, Deng T, Amato AA, Togashi M, Hsueh WA, Phillips K, Palma MS, Neves FA, Skaf MS, Webb P, Polikarpov I. 2012. Medium Chain Fatty Acids Are Selective Peroxisome Proliferator activated Receptor (PPAR) c Activators and Pan−PPAR Partial Agonists. Plos One 7 e36297.
・Liu J, Li H, Burstein SH, Zurier RB, Chen JD. 2003. Activation and binding of peroxisome proliferator−activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 63: 983−992.
・Monks TJ, Jones DC. 2002. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone−thioethers. Curr Drug Metab. 4:425−38.
・Morales P, Vara D, Gomez−Canas M, Zuniga MC, Olea−Azar C, Goya P, Fernandez−Ruiz J, Daiz−Laviada I, Jagerovic N. 2013. Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. Eur J Med Chem. 70: 111−119.
・Na HK, Surh YJ. 2013. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase−1. Free Radic Biol Med. 67:353−365
・Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV.1998. Ligand binding and co−activator assembly of the peroxisome proliferator−activated receptor−gamma. Nature 395: 137−143.
・O’Sullivan SE. 2007. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator−activated receptors. Br J Pharmacol. 152:576−82.
・Poulsen L, Siersbaek M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. 2012. Semin Cell Dev Biol. 23:631−639.
・Rosen ED, MacDougald OA. 2006. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 7:885−96.
・Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II. 2010. Nrf2 and Keap1 abnormalities in non−small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 16:3743−53
・M.B. Sporn, K.T. Liby. 2012. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer. 12: 564−57
・Stienstra R, Duval C, Muller M, Kersten S, 2007. PPARs, obesity, and inflammation. PPAR Res. 95974.
・Sun Y, Bennett A. 2007. Cannabinoids: A New Group of Agonists of PPARs. PPAR Res. 23513.
・Szeles, L., Toeroesik, D., Nagy, L., 2007. PPARgamma in immunity and inflammation: cell types and diseases. Biochim. Biophys. Acta 1771: 1014−1030.
・Tachibana K, Yamasaki D, Ishimoto K, Doi T. 2008. The Role of PPARs in Cancer. PPAR Res. 102737.
・Tontonoz P, Spiegelman BM. 2008. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 77: 289−312.
・Vanden Berghe W, Vermeulen L, Delerive P, DeBosscher K Staels B, Haegeman G. 2003. A paradigm for gene regulation: inflammation, NF−kB and PPAR. Adv.Exp.Med.Biol. 544:181−196.
・Vivacell Biotechnology Espana, S.L. 2011. Cannabinoid quinone derivatives. WO 2011117429 A1.
・Wang W, Liu F, Chen N. 2007. Peroxisome proliferator−activated receptor−gamma (PPAR−gamma) agonists attenuate the profibrotic response induced by TGF−beta1 in renal interstitial fibroblasts. Mediators Inflamm: 62641
・Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. 2006. PPARgamma agonists prevent TGFbeta1/Smad3−signaling in human hepatic stellate cells. Biochem Biophys Res Commun. 350: 385−391.
・Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen XL. Guo SZ, Gao WY. 2009. Troglitazone suppresses transforming growth factor−beta1−induced collagen type I expression in keloid fibroblasts. Br J Dermatol. 160:762−70
Claims (8)
- 式(I)の化合物またはその薬学的に許容可能な塩であって、
- 以下から選択される請求項1に記載の化合物。
- 式Iの化合物またはその薬学的に許容可能な塩を含む組成物であって、
- 式Iの化合物は以下から選択される、請求項3に記載の組成物。
- PPRAg媒介性の疾患の処置のための製剤またはその薬学的に許容可能な塩の製造における請求項1または2に記載の化合物の使用。
- PPRAg媒介性の疾患は、アテローム性動脈硬化、炎症性腸疾患、関節リウマチ、肝臓繊維症、腎症、乾癬、皮膚創傷治癒、皮膚再生、膵炎、胃炎、神経変性障害、神経炎症障害、強皮症、癌、高血圧、肥満、またはII型糖尿病から選択される請求項5に記載の使用。
- PPRAg媒介性の疾患の処置のための製剤の製造における請求項3または4に記載の組成物の使用。
- PPRAg媒介性の疾患は、アテローム性動脈硬化、炎症性腸疾患、関節リウマチ、肝臓繊維症、腎症、乾癬、皮膚創傷治癒、皮膚再生、膵炎、胃炎、神経変性障害、神経炎症障害、強皮症、癌、高血圧、肥満、またはII型糖尿病から選択される請求項7に記載の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2014/057767 WO2015158381A1 (en) | 2014-04-16 | 2014-04-16 | Novel cannabidiol quinone derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017516753A JP2017516753A (ja) | 2017-06-22 |
JP6167248B2 true JP6167248B2 (ja) | 2017-07-19 |
Family
ID=50693623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016560647A Active JP6167248B2 (ja) | 2014-04-16 | 2014-04-16 | 新規なカンナビジオールキノン誘導体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9701618B2 (ja) |
EP (1) | EP3131874B1 (ja) |
JP (1) | JP6167248B2 (ja) |
KR (1) | KR102256398B1 (ja) |
CN (1) | CN106232570B (ja) |
AU (1) | AU2014390738B2 (ja) |
BR (1) | BR112016023902A2 (ja) |
CA (1) | CA2945867C (ja) |
DK (1) | DK3131874T3 (ja) |
ES (1) | ES2692693T3 (ja) |
IL (1) | IL248030B (ja) |
MX (1) | MX352386B (ja) |
RU (1) | RU2667504C2 (ja) |
WO (1) | WO2015158381A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017406103B2 (en) * | 2017-03-29 | 2023-12-14 | Emerald Health Pharmaceuticals, Inc. | Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity |
CN106866419B (zh) * | 2017-04-14 | 2020-01-10 | 石河子大学 | 一类萜酯化合物及其制备方法和用途 |
AU2018287018B2 (en) * | 2017-06-20 | 2022-04-28 | University Of Guelph | Cannabidiolic acid esters compositions and uses thereof |
US20220041538A1 (en) * | 2018-12-11 | 2022-02-10 | Emerald Health Pharmaceuticals Inc | Cannabigerol quinone acid and salts thereof |
JP2022519685A (ja) * | 2019-02-06 | 2022-03-24 | エメラルド ヘルス ファーマシュウティカルズ インコーポレイテッド | カンナビジオール誘導体の製剤およびカンナビノイド受容体タイプ2(cb2)のモジュレーターとしてのその使用 |
JP2022550797A (ja) | 2019-10-03 | 2022-12-05 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | リポソームカンナビノイドおよびその使用 |
WO2021139741A1 (zh) * | 2020-01-08 | 2021-07-15 | 成都百裕制药股份有限公司 | 大麻二酚衍生物及其制备方法和在医药上的应用 |
EP4099993A4 (en) * | 2020-02-06 | 2024-03-13 | Emerald Health Pharmaceuticals Inc. | COMPOSITION AND METHOD FOR TREATING AND PREVENTING CARDIAC, LUNG, SKIN AND KIDNEY FIBROSIS |
EP4267122A4 (en) * | 2020-12-24 | 2024-04-24 | Buzzelet Development And Technologies Ltd | COMPOSITIONS COMPRISING CANNABINOID ACID ESTERS |
CN114315585B (zh) * | 2022-03-04 | 2022-05-13 | 中国医学科学院药用植物研究所 | 一种羟戊苯甲酸双酯化合物及其制备方法和制药应用 |
CN116407529B (zh) * | 2023-03-24 | 2024-05-10 | 南京医科大学 | 3-硝基-2,6-二羟基苯甲酸右崁醇或葑醇的酯的药物用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL159892A0 (en) * | 2004-01-15 | 2004-06-20 | Yissum Res Dev Co | Use of quinonoid derivatives of cannabinoids in the treatment of malignancies |
US20090093521A1 (en) * | 2005-06-14 | 2009-04-09 | Maria Laura Bolognesi | 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives |
EP2139847A1 (en) * | 2007-03-05 | 2010-01-06 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies |
WO2011117429A1 (es) | 2010-03-26 | 2011-09-29 | Vivacell Biotechnology España, S.L | Derivados quinona de cannabinoides |
WO2012012498A2 (en) * | 2010-07-20 | 2012-01-26 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
-
2014
- 2014-04-16 WO PCT/EP2014/057767 patent/WO2015158381A1/en active Application Filing
- 2014-04-16 ES ES14723345.6T patent/ES2692693T3/es active Active
- 2014-04-16 AU AU2014390738A patent/AU2014390738B2/en active Active
- 2014-04-16 KR KR1020167030311A patent/KR102256398B1/ko active IP Right Grant
- 2014-04-16 DK DK14723345.6T patent/DK3131874T3/en active
- 2014-04-16 BR BR112016023902A patent/BR112016023902A2/pt not_active Application Discontinuation
- 2014-04-16 CA CA2945867A patent/CA2945867C/en active Active
- 2014-04-16 JP JP2016560647A patent/JP6167248B2/ja active Active
- 2014-04-16 EP EP14723345.6A patent/EP3131874B1/en active Active
- 2014-04-16 RU RU2016137668A patent/RU2667504C2/ru active
- 2014-04-16 US US15/304,810 patent/US9701618B2/en active Active
- 2014-04-16 CN CN201480078012.4A patent/CN106232570B/zh active Active
- 2014-04-16 MX MX2016013151A patent/MX352386B/es active IP Right Grant
-
2016
- 2016-09-25 IL IL24803016A patent/IL248030B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL248030A0 (en) | 2016-11-30 |
BR112016023902A2 (pt) | 2017-08-15 |
CA2945867C (en) | 2021-11-09 |
CN106232570A (zh) | 2016-12-14 |
RU2667504C2 (ru) | 2018-09-21 |
EP3131874A1 (en) | 2017-02-22 |
AU2014390738A1 (en) | 2016-10-27 |
JP2017516753A (ja) | 2017-06-22 |
CN106232570B (zh) | 2018-08-07 |
KR102256398B1 (ko) | 2021-05-27 |
WO2015158381A1 (en) | 2015-10-22 |
AU2014390738B2 (en) | 2019-05-02 |
KR20160146765A (ko) | 2016-12-21 |
DK3131874T3 (en) | 2018-11-19 |
RU2016137668A3 (ja) | 2018-05-16 |
EP3131874B1 (en) | 2018-07-25 |
ES2692693T3 (es) | 2018-12-04 |
US9701618B2 (en) | 2017-07-11 |
US20170044092A1 (en) | 2017-02-16 |
RU2016137668A (ru) | 2018-05-16 |
MX352386B (es) | 2017-11-22 |
CA2945867A1 (en) | 2015-10-22 |
IL248030B (en) | 2019-10-31 |
MX2016013151A (es) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6167248B2 (ja) | 新規なカンナビジオールキノン誘導体 | |
CA2584485C (en) | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | |
DK2943467T3 (en) | Benzylidenguanidinderivativer and therapeutic use for the treatment of diseases associated with improper protein folding | |
JP6619349B2 (ja) | 新規なカンナビゲロール誘導体 | |
KR101352635B1 (ko) | 신규 혈관누출 차단제 | |
JP5575324B2 (ja) | カンナビノイド・キノン誘導体 | |
JP2017521494A (ja) | プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用 | |
JP6598224B2 (ja) | ヒドロキサメートトリテルペノイド誘導体 | |
RU2734253C2 (ru) | Тиазолидиноновые соединения и их применение для лечения психических или неврологических нарушений и воспаления, в частности нейровоспаления | |
JP7140325B2 (ja) | 化合物、抗アレルギー剤およびメディエーター遊離阻害剤 | |
Wang et al. | Design and synthesis of salidroside analogs and their bioactivity against septic myocardial injury | |
Lakshmi Narayanan et al. | EVALUATION OF ANALGESIC AND ANTI INFLAMMATORY ACTIVITY OF SOME SYNTHESIZED 3-(5-PHENYL-4, 5-DIHYDRO-1-SUBSTITUTEDPYRAZOL-3-YL) CHROMEN-2-ONE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20170324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170525 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170531 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170626 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6167248 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |